NCT06066424View on ClinicalTrials.gov

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

PHASE1RecruitingINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

April 30, 2038

Study Completion Date

April 30, 2040

Conditions

Solid Tumors

Interventions

DRUG

Rimiducid

Given by (IV) vein

DRUG

TROP2-CAR-NK Cells

Given by (IV) vein

DRUG

Fludarabine phosphate

Given by (IV) vein

DRUG

Cyclophosphamide

Given by (IV) vein

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bellicum Pharmaceuticals

All Listed Sponsors

collaborator

Bellicum Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER